Prolonged pharmacotherapy and the eye. A symposium. The antimalarials and the tranquilizers.
D000818:Animals; D000962:Antimalarials / Q000009:adverse effects*; D002247:Carbon Isotopes; D002738:Chloroquine / Q000009:adverse effects; D003315:Cornea / Q000187:drug effects; D005128:Eye Diseases / Q000139:chemically induced*; D005260:Female; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D008266:Macula Lutea; D008297:Male; D008543:Melanins / Q000378:metabolism; D009696:Nucleic Acids / Q000378:metabolism; D010640:Phenothiazines / Q000009:adverse effects*; D010859:Pigmentation Disorders / Q000139:chemically induced*; D011804:Quinolines / Q000009:adverse effects; D012160:Retina / Q000187:drug effects; D012877:Skin Manifestations; D013460:Sulfur Isotopes; D014149:Tranquilizing Agents / Q000009:adverse effects*; D014316:Tritium
D000962:Antimalarials; D002247:Carbon Isotopes; D006025:Glycosaminoglycans; D008543:Melanins; D009696:Nucleic Acids; D010640:Phenothiazines; D011804:Quinolines; D013460:Sulfur Isotopes; D014149:Tranquilizing Agents; D014316:Tritium; D002738:Chloroquine